Sarcopenia
Conditions
Brief summary
Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.
Interventions
A dietary supplement provided as powder dissolved in a glass of water
A dietary supplement provided as powder dissolved in a glass of water
Sponsors
Study design
Eligibility
Inclusion criteria
* Age \> 70 years * Free of acute disorders
Exclusion criteria
* History of dietary supplement use during the past 4 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in muscular strength | Baseline vs. 6 months post-intervention | Baseline vs. 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in muscle mass | Baseline vs. 6 months post-intervention | Baseline vs. 6 months |
| Change in muscle metabolites evaluated with MR spectroscopy | Baseline vs. 6 months post-intervention | Baseline vs. 6 months |
| Change in cognitive performance evaluated with Mini-Mental State Exam test | Baseline vs. 6 months post-intervention | Baseline vs. 6 months |
| Change in serum creatine | Baseline vs. 6 months post-intervention | Baseline vs. 6 months |
Countries
Serbia